Paper Details

  1. Home
  2. Paper Details

The intraocular pressure responses of low-dose bupranolol (Ophtorenin) and methazolamide (Neptazane) in glaucomatous eyes. A controlled clinical study.

Author: KrieglsteinG K, LeydheckerW

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Controlled Clinical TrialA clinical trial that evaluates the effectiveness of a treatment by comparing a group that receives the intervention with a group that receives a placebo or standard treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Bupranolol and methazolamide were both effective in reducing intraocular pressure. The combined application of these two drugs may postpone or avoid side effects and prolong the time and the field of clinical usefulness.
Paper Details　
Original Abstract of the Article :
In a single-dose, double-blind study, the minimum effective doses of bupranolol and methazolamide were established. The beta-blocker bupranolol (Ophtorenin, Dr. Winzer, Konstanz) in an oily solution reduced IOP significantly in a concentration of 0.05%. The carboanhydrase inhibitor Methazolamide (Ne...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/BF00409999

データ提供：米国国立医学図書館（NLM）

A Synergistic Approach to Glaucoma Treatment

Glaucoma, a condition that damages the optic nerve, can lead to vision loss. This study explores the intraocular pressure (IOP) responses of low-dose bupranolol and methazolamide, two medications used to treat glaucoma. It's like exploring two different oases in the desert, seeking the most effective treatment approach for glaucoma.

A Combined Strategy for Lowering IOP

The study found that both bupranolol and methazolamide effectively reduced IOP. This is like discovering two separate water sources that can quench our thirst. However, the combination of both drugs exhibited an additive effect, suggesting that this approach might be more effective. This is akin to finding a single oasis that offers both fresh water and shade, providing a more comprehensive solution.

A More Effective Way to Treat Glaucoma

The combined application of bupranolol and methazolamide could potentially delay or prevent side effects, extending the usefulness of these medications. This is like building a sturdy shelter in the desert, providing a more sustainable and comfortable solution for managing glaucoma.

Dr.Camel's Conclusion

This study sheds light on a more effective approach to treating glaucoma. By combining two different medications, we can potentially achieve better control of IOP and minimize the risk of side effects. This is like finding a hidden treasure in the desert, offering a more comprehensive and sustainable solution for managing this challenging condition.

Date :
  1. Date Completed 1979-06-26
  2. Date Revised 2019-09-11
Further Info :

Pubmed ID

373489

DOI: Digital Object Identifier

10.1007/BF00409999

Related Literature

Article Analysis
・Side Effects of methazolamide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.